Back to results
US 2022/0054513 A1Published application
Combination compositions comprising a beta-lactamase inhibitor
AssigneeVenatorx Pharmaceuticals, Inc.
InventorsJodie HAMRICK, Christopher J. BURNS, Daniel C. PEVEAR, Luigi XERRI, Timothy HENKEL, Denis DAIGLE
Life of this patent
Estimating the term…
Abstract
Described herein are combination compositions comprising a beta-lactamase inhibitor. In certain embodiments, the combination compositions described herein are useful in the treatment of bacterial infections.
Claims107
A method of treating a bacterial infection comprising administering a pharmaceutical composition comprising:
- (i) (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid:
- a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof;
- and
- (ii) a siderophore antibiotic.
1 more element
A method of treating a bacterial infection comprising administering a pharmaceutical composition comprising:
- (i) (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid:
- a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof;
- and
- (ii) sulbactam.
1 more element
A method of treating a bacterial infection comprising administering a pharmaceutical composition comprising:
- (i) (R)-3-(2-(trans-4-(2-aminoethylamino)cyclohexyl)acetamido)-2-hydroxy-3,4-dihydro-2H-benzo[e][1,2]oxaborinine-8-carboxylic acid:
- a pharmaceutically acceptable salt, a solvate, or a pharmaceutically acceptable salt and solvate thereof;
- and
- (ii) tazobactam.
1 more element
Dependencies are inferred from the claim text.